Advertisement

Topics

Arrhythmogenic Substrate in Primary Cardiomyopathies

2017-10-16 17:33:11 | BioPortfolio

Published on BioPortfolio: 2017-10-16T17:33:11-0400

Clinical Trials [1013 Associated Clinical Trials listed on BioPortfolio]

Amiodarone Usage After Ischemic Ventricular Tachycardia Ablation

Ventricular Tachycardia ablation in ischemic cardiomyopathy patients is required procedure in cases when anti-arrhythmic drugs failed. The concern is if adjunctive continuation amiodarone ...

Risk Stratification in Children and Adolescents With Primary Cardiomyopathy

RIKADA is a prospective study performing systematic family screening including clinical and genetic testing in pediatric patients with primary cardiomyopathy and their first-degree relativ...

Catheter Ablation for Nonsustained Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy

Despite established implantable cardioverter-defibrillator (ICD) therapy and catheter ablation for sustained ventricular tachycardia (VT) in patients with ischemic heart disease (IHD) and ...

Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy

Paroxysmal or chronic atrial fibrillation (AF) develops in about 20- 25% of adult patients with hypertrophic cardiomyopathy (HCM) and represents an important complication in the clinical c...

Cardiomyopathy Arrhythmia Risk Evaluation

This study will evaluate the prognostic utility of novel ECG markers of electrical instability in patients with cardiomyopathy.

PubMed Articles [7142 Associated PubMed Articles listed on BioPortfolio]

Characteristics of Recurrent Ventricular Tachyarrhythmia after Catheter Ablation in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy.

The reason for recurrence of ventricular arrhythmia (VA) after catheter ablation in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) is not clear.

Letter by Sherrid et al Regarding Article, "Bail-Out Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy in a Patient With Takotsubo Cardiomyopathy-Induced Cardiogenic Shock".

Ablation Compared to Drug Therapy for Recurrent Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy; Results from a Multicenter Study.

The comparative efficacy of antiarrhythmic drug therapy (AAD) versus ventricular tachycardia (VT) ablation in arrhythmogenic right ventricular cardiomyopathy (ARVC) is unknown.

Recurrent ventricular tachycardia after catheter ablation in arrhythmogenic right ventricular cardiomyopathy: Scar progression or ineffective ablation?

Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.

There is evidence that implantable cardioverter-defibrillator (ICD) for primary prevention in people with an ischaemic cardiomyopathy improves survival rate. The evidence supporting this intervention ...

Medical and Biotech [MESH] Definitions

A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).

Removal of tissue by vaporization, abrasion, or destruction. Methods used include heating tissue by hot liquids or microwave thermal heating, freezing (CRYOABLATION), chemical ablation, and photoablation with LASERS.

An autosomal dominant inherited form of HYPERTROPHIC CARDIOMYOPATHY. It results from any of more than 50 mutations involving genes encoding contractile proteins such as VENTRICULAR MYOSINS; cardiac TROPONIN T; ALPHA-TROPOMYOSIN.

A congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the RIGHT VENTRICLE wall and loss of myocardial cells. Primary injuries usually are at the free wall of right ventricular and right atria resulting in ventricular and supraventricular arrhythmias.

A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

More From BioPortfolio on "Arrhythmogenic Substrate in Primary Cardiomyopathies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial